Pharma channel feed

With sub­par sales for Leqem­bi, Ei­sai de­lays Alzheimer’s pa­tient goal dead­line

Last year

Lil­ly ax­es PhI­II tri­al of Verzenio in prostate can­cer

Last year
R&D

Lil­ly's weight loss drug Zep­bound gen­er­ates $175M with­in weeks as Moun­jaro sales al­so soar

Last year

Ver­tex un­veils cys­tic fi­bro­sis da­ta, talks of us­ing pri­or­i­ty re­view vouch­er

Last year
FDA+

No­var­tis to buy Mor­phoSys for $2.9B af­ter 20 years of cre­at­ing an­ti­bod­ies with the Ger­man biotech

Last year
Deals

Van­da takes is­sue with FDA's re­lay of de­fi­cien­cies for new Het­lioz in­di­ca­tion

Last year
FDA+

Mak­ers of block­buster weight loss drugs are us­ing 'patent thick­et­s' to pro­tect prod­ucts, Har­vard study claims

Last year
FDA+

Up­dat­ed: Astel­las low­ers sales ex­pec­ta­tions for menopause drug, aims to ‘re­pro­duce’ hype for Veozah with an­oth­er Su­per Bowl ad

Last year
Marketing

New Te­va ad cam­paign fo­cus­es on pa­tients strug­gling with psy­chi­atric drug side ef­fect

Last year
Marketing

Fed­er­al judge toss­es out an­titrust law­suit against Eli Lil­ly, Sanofi over di­a­betes drug dis­counts

Last year
Law

Amer­i­can Bar As­so­ci­a­tion says low­er court was 'ill-equipped' to re­strict abor­tion pill use

Last year
FDA+
Law

Sanofi de­buts glob­al can­cer sup­port pro­gram for em­ploy­ees

Last year
Marketing

Draft 340B re­forms in­clude user fees, clar­i­ty around con­tract phar­ma­cies

Last year
FDA+
Law

Abec­ma sales dis­ap­point again as BC­MA com­pe­ti­tion ramps up, FDA ad­comm looms

Last year
Cell/Gene Tx

Hik­ma to pay $115M in cash, $35M in do­na­tions to set­tle opi­oid claims

Last year
Law

Re­al Hu­mi­ra com­pe­ti­tion may not ar­rive un­til 2026, Ab­b­Vie ex­ecs tell in­vestors

Last year
R&D

For­mer FDA com­mis­sion­ers urge SCO­TUS to pre­serve agency’s reg­u­la­tions of abor­tion pill

Last year
FDA+
Law

Rick Gon­za­lez lays out plan for in­ter­nal can­di­date to take over as Ab­b­Vie's CEO

Last year
People

Re­gen­eron aims to stop mus­cle loss with com­bi­na­tion treat­ment ap­proach in obe­si­ty

Last year
R&D

Un­like Mer­ck, Bris­tol My­ers to fo­cus on bolt-ons af­ter M&A spree

Last year
Deals

Take­da says farewell to CFO, suite of clin­i­cal-stage pro­grams in Q3 up­date

Last year
R&D

Pub­li­cis Health set­tles opi­oid law­suit

Last year
Marketing
Law

Mer­ck high­lights sub­cu­ta­neous de­mand even as Keytru­da sales soar

Last year

Just how low did the gov­ern­ment go with first IRA of­fers? Phar­ma’s not telling

Last year
First page Previous page 75767778798081 Next page Last page
A service from the Financial Times